BioSpecifics Technologies Corp (BSTC) financial statements (2021 and earlier)
Company profile
| Business Address |
35 WILBUR ST LYNBROOK, NY 11563 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 87 | 99 | 104 | 89 | 82 | 85 | 84 | ||
| Cash and cash equivalents | 3 | 17 | 19 | 5 | 13 | 14 | 18 | ||
| Short-term investments | 84 | 82 | 85 | 84 | 69 | 71 | 67 | ||
| Receivables | 14 | 12 | 18 | 19 | 18 | 17 | 16 | ||
| Prepaid expense | 1 | ||||||||
| Other undisclosed current assets | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Total current assets: | 102 | 112 | 123 | 109 | 101 | 103 | 102 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 0 | 0 | 0 | 0 | |||||
| Property, plant and equipment | 0 | 0 | 0 | ||||||
| Long-term investments and receivables | 34 | 21 | 9 | 17 | 16 | 8 | 4 | ||
| Long-term investments | 34 | 21 | 9 | 17 | 16 | 8 | 4 | ||
| Intangible assets, net (including goodwill) | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||
| Intangible assets, net (excluding goodwill) | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||
| Other noncurrent assets | 0 | 0 | 0 | ||||||
| Other undisclosed noncurrent assets | 0 | 0 | |||||||
| Total noncurrent assets: | 35 | 22 | 10 | 17 | 17 | 9 | 4 | ||
| TOTAL ASSETS: | 137 | 134 | 133 | 127 | 118 | 112 | 106 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1 | 2 | 2 | 1 | 1 | 1 | 2 | ||
| Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Accrued liabilities | 1 | 1 | 0 | 0 | 1 | 0 | 1 | ||
| Employee-related liabilities | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Taxes payable | 0 | ||||||||
| Other undisclosed accounts payable and accrued liabilities | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||
| Debt | 0 | 0 | 0 | ||||||
| Other undisclosed current liabilities | 0 | 2 | 2 | 0 | 1 | 2 | |||
| Total current liabilities: | 2 | 4 | 3 | 1 | 1 | 2 | 4 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 0 | 0 | 0 | 0 | |||||
| Operating lease, liability | 0 | 0 | 0 | 0 | |||||
| Liabilities, other than long-term debt | 0 | 0 | 0 | 1 | 1 | ||||
| Deferred income tax liabilities | 0 | 0 | 0 | 1 | 1 | ||||
| Total noncurrent liabilities: | 0 | 1 | 1 | 1 | 1 | ||||
| Total liabilities: | 2 | 4 | 4 | 2 | 1 | 2 | 4 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 135 | 129 | 129 | 124 | 117 | 110 | 102 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Treasury stock, value | (12) | (12) | (12) | (12) | (11) | (11) | (11) | ||
| Additional paid in capital | 41 | 40 | 40 | 39 | 39 | 38 | 37 | ||
| Retained earnings | 107 | 101 | 101 | 97 | 89 | 83 | 77 | ||
| Total stockholders' equity: | 135 | 129 | 129 | 124 | 117 | 110 | 102 | ||
| TOTAL LIABILITIES AND EQUITY: | 137 | 134 | 133 | 127 | 118 | 112 | 106 | ||
Income statement (P&L) ($ in millions)
| 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 11 | 4 | 10 | 12 | 9 | 9 | 8 | |
| Cost of revenue | (1) | |||||||
| Gross profit: | 10 | 4 | 10 | 12 | 9 | 9 | 8 | |
| Operating expenses | (3) | (4) | (4) | (3) | (2) | (2) | (3) | |
| Operating income (loss): | 7 | (0) | 5 | 9 | 7 | 7 | 5 | |
| Nonoperating income | 0 | 0 | 0 | 1 | 1 | 1 | 0 | |
| Investment income, nonoperating | 0 | 0 | 0 | 1 | 1 | 0 | ||
| Income from continuing operations before income taxes: | 7 | 0 | 6 | 9 | 8 | 7 | 6 | |
| Income tax expense | (1) | (0) | (1) | (2) | (2) | (1) | (1) | |
| Net income available to common stockholders, diluted: | 5 | 0 | 4 | 7 | 6 | 6 | 4 | |
Comprehensive Income ($ in millions)
| 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income: | 5 | 0 | 4 | 7 | 6 | 6 | 4 | |
| Comprehensive income, net of tax, attributable to parent: | 5 | 0 | 4 | 7 | 6 | 6 | 4 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.